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CDC Rift Valley fever Vaccine Initiative

Brian Bird DVM, MSPH, PhD
Viral Special Pathogens Branch
Centers for Disease Control and Prevention

Viral Special Pathogens Branch
• Focus on viral hemorrhagic fevers
(>35 viruses, 5 Families)
– BSL-4, BSL-3+, BSL-2 labs

• Diagnostics – Outbreak Response
– Serology, molecular, Next-Gen
sequencing

• Epidemiology
• Laboratory Science
– molecular biology, pathogenesis,
immunology, vaccines and anti-viral
therapeutic drugs

• Ecology
– Uganda (Ebola, Marburg)
– South America (hantaviruses)
– Eastern and Southern Africa (RVF)

Rift Valley fever virus
• Mosquito-borne RNA virus (Bunyaviridae)
•

(Aedes sp. mosquitoes most important)

• Endemic throughout Africa and parts of Arabian
Peninsula
• Outbreaks linked to extensive rainfall – mosquito
abundance
• Outbreaks are extensive
•
•

humans (10s to 100s thousands)
livestock (millions)

• Threat of introduction into Middle East, Europe or US
•

Many competent mosquito vectors in North America

• Potential bioterrorism threat

RVF disease
• Humans

• Majority: self limiting
febrile illness
~1-2% of cases
ACUTE: hepatitis >
hemorrhagic syndrome
• (10-20% case fatality)

DELAYED: encephalitis, retinitis,
blindness

• Direct contact with infected
livestock is the key risk factor
for severe and lethal disease

RVF disease
• Livestock

• Sheep, cattle, goats
• Camelids

• Abortion storms

• near 100% sheep and cattle

• High newborn mortality
• 80-100%

• Adult mortality
• 5-20%

• Wildlife: Cape Buffalo transient viremia,
many other species IgG positive
• Horses, swine, poultry unaffected

Current status of RVF vaccines
• No commercially available human or livestock
vaccines for use in the U.S. and Europe
• Exciting time in RVFV vaccine research
– Recombinant MLAV, VLP, VRP, Paramyxo vectored, Pox
virus vectored etc.

• A couple of livestock vaccines in limited use in Africa
(OBP, South Africa):
– inactivated vaccine
– live attenuated vaccines: Smithburn strain
• abortions, teratology, other fetal abnormalities
• No capacity to differentiate vaccinated from
naturally infected animals
• Clone 13 LAV may be an improvement with fewer
adverse effects

CDC RVF vaccine development strategy
• Virus amplification in livestock leads to explosive outbreaks and is
needed to get spillover into humans
• Disease in livestock precedes disease in humans by ~ 1 month
• Significantly easier to get vaccines approved for livestock than
humans
• One Health – good livestock vaccines should indirectly reduce or
prevent human disease
• Vaccine design should allow for further development in humans
– (FDA animal rule)

…or why is CDC working on a livestock vaccine ???
Don’t you work on people diseases???

One Health – good livestock
vaccines should indirectly
reduce or prevent human
disease

Bird and Nichol
Curr Opinion in Virol,2012

Ideal RVF vaccine properties
• Precise identity and excellent purity
• Safety – No post-vax disease; no abortions or fetal
abnormalities (Historically this has been a BIG problem)
• Single dose, rapid and long lasting protection
- best achieved with live attenuated vaccine

• Multiple attenuating lesions/ absence of reversion
• Inexpensive (produced at high titers = cheap/dose)
• Differentiate infected from vaccinated animals
- DIVA

Towards rational vaccine design
• Reverse genetics approach
– Generation of precisely engineered infectious virus
from plasmid DNA
– Identify and knock out critical virus virulence genes
– Use these modified viruses as vaccine candidates
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∆/∆ Vax

Rodent results (~6yrs)
• Excellent safety with either candidate
when given at doses up to 10,000x LD50 of
virulent virus (LD50 = < 1.0 PFU)
• Complete protection from up to 10,000x
LD50 dose of virulent virus 28 days post-vax
Robust IgG response >1:6400
• PRNT80 >1:1256

• Rapid protection up to 100% within
48 hours postpost-vaccination in mice

Rodent results
• Excellent safety with either candidate
when given at doses up to 10,000x LD50 of
virulent virus
• Complete protection from up to 10,000x
LD50 dose of virulent virus 28 days post-vax
Robust IgG response >1:6400
• PRNT80 >1:1256

BUT WHAT ABOUT A
RELEVANT HOST?????

∆/∆ Vaccine Sheep Trial
Bird et al., Journal of Virology 2011

Deltamune Pty. Ltd. South Africa
• Safety and Efficacy Trial
•
•
•
•

timed pregnant ewes
1.0x104 PFU SC
N=29 vaccinates, N=3 sham controls
Vacc. at day 42 gestation:
• (fetus most sensitive to teratogenesis, MP12/Smithburn)

∆/∆ Vaccine Trial Timeline
Dr. Barbara Knust
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∆/∆ Vaccine Trial Timeline
Safety 2: NO CHALLENGE,
Monitor through full-term N=20
Safety 1 : Vax early gestation:
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∆/∆ Safety and Immunogenicity
post--Vaccination
post

Shelley Campbell

All vaccinated animals (N=29) seroconverted
No fever detected post-vaccination
No other adverse events detected
No seroconversion in contact controls (N=3)

∆/∆ EFFICACY
• Challenge (n=9) at Day 121 pregnancy or 82 days post-vax

• No abortion or viremia in vaccinated animals
– Vacc. ewes: NO viremia or fever; day 1 to 14
– Lambs born to vacc ewes: virus neg. (blood, liver, brain)

• All shams (n=3) aborted by day 6 PC
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Differentiating Infected from Vaccinated Animals
Polymerase

• recombinant proteins

Vax animals:
• NP + only

Infected animals:
• NP+
• NSs+
• NSm+
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Built into vaccine design
• 3-way ELISA assay
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Ideal RVF vaccine properties
Precise identity and excellent purity
– generated from plasmid DNA of 100% exact sequence

Safety - ∆/∆ NOT a Select Agent, RSA and CDC IBC = BSL-2, awaiting
more broad NIH RAC classification
– NO adverse events in rodents (n~350)
– NO adverse event in adult or pregnant sheep (n=42 total)

Single dose rapid protection
– Mice 100% protection by 48-72 hrs

Multiple attenuating lesions/ avoid reversion
– 2 complete virus gene deletions

Differentiate infected from vaccinated animals
– DIVA based on vaccine lacking NSs and NSm genes

Excellent “Environmental containment”
– Does not infect mosquito vectors (Crabtree et al, PLoS NTD 2012); no viremia in vaccinates

Inexpensive
– ∆/∆ grows > 107 pfu/ml in routine VERO cell culture
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Lake Naivasha, Kenya
Site of first reported RVF outbreak 1930

